Navigation Links
Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Date:3/11/2008

nt options with curative potential, recurrence is common within the first 12 to 15 months following surgery and five-year survival following resection is less than 50%.

Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs, added, "Since the release of our promising phase 2 data last year, our team has worked tirelessly to design a world-class phase 3 trial for PI-88 in liver cancer. We are very thankful for the support of key opinion leaders and clinicians all over the world, many of whom will now be serving as investigators in PATHWAY. While the study is starting later than we had hoped as a result of some delays opening sites due to a greater-than-expected impact from holidays over the past couple of months, Progen continues to aggressively drive country regulatory and hospital ethics approvals to conduct this phase 3 trial."

The study now has regulatory approval in almost half of the participating countries and more than a dozen sites have been granted approval by ethics committees. Sites are being initiated so as to be able to commence patient recruitment as soon as these necessary approvals have been granted.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In April 2007, data from a randomised phase 2 trial in the post resection liver cancer setting was presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain. PI-88, in this disease setting, has been granted Orphan Drug designation by the European Medicines Evaluation Agency (EMEA) and Fast Track designation by the United States Food and Drug Administration (FDA).
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... Ontario , Nov. 20, 2014  RedRick ... mounting solutions and reading room environment guidance, has ... newest musculoskeletal radiology reading room, which may also ... designs at Penn Medicine. "In ... the American College of Radiology,s Imaging 3.0 ™ ...
(Date:11/21/2014)...   Coqui RadioPharmaceuticals Corp. , a medical isotope ... of Molybdenum-99 (Mo-99), is proud to announce it has ... design its Medical Isotope Production Facility (MIPF) in ... isotope of Technetium-99, which is used in 80 percent ... legislation making it a national priority to produce Mo-99, ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Del., May 14, 2012  Synchrogenix Information Strategies Inc., a ... to announce the addition of a new office in ... Synchrogenix CEO, Ellen Barrosse, has appointed Bengt Olsson ... company,s newest office, located in Stockholm, Sweden.  With more ...
... 14, 2012  Eli Lilly and Company (NYSE: LLY ... its clinical oncology pipeline during the 48th Annual Meeting of ... Ill. from June 1 – 5, 2012. ... late-stage development to treat various types of cancer. The company ...
Cached Medicine Technology:Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 2Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 3Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 4
(Date:11/23/2014)... has recently announced that its Special Friday Shoes sales, ... offer will provide ladies many gorgeous shoes at greatly discounted ... women’s dresses retailers, and its shoes include many models in ... that day: Everything at Tbdress.com is up to 90% off. ... People can use the following coupon codes as well: , ...
(Date:11/23/2014)... 21, 2014 (HealthDay News) -- Close friends have more ... group does, a new study says. "We,ve ... have an influence on individual alcohol use, but there ... peer group and the friend group,s influence on those ... School of Public Health, said in a university news ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... DC (PRWEB) November 23, 2014 “BlackVue” ... Tech Report , which features the latest and ... technology expert and reporter for NewsWatch, conducted the product ... are unique and powerful options in the car camera ... rising and it can be hard to find the ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Tips for using the full line of dermatologist ... The Theraplex Company, the,makers of a full line ... range of dry skin conditions, is launching its ... and advice for,healthy looking and beautiful skin. Four ...
... Schizophrenia emerges from an altered pattern of brain development, ... cause the brain to develop along a path that ... article to be published in Biological Psychiatry on March ... link to schizophrenia. , A prior genetic mapping study ...
... TotalLook MammoAdvantage(TM)Provides Enhanced Image Quality, Customization ... and Workflow Benefits to Mammography ... Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection ... announced the,availability of the TotalLook MammoAdvantage system which ...
... can used to diagnose severity of bipolar illness , , ... blood associated with mood disorders have been identified by ... finding may change the way bipolar illness is diagnosed ... 96 patients and found varying levels of the biomarkers ...
... renters told Apartments.com, during national heart, awareness month, ... of on-site fitness facilities offered ... The majority of renters lead a healthy,lifestyle by eating ... would also,prefer to step up their current workout routine ...
Cached Medicine News:Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:New genetic association with schizophrenia found by researchers 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 3Health News:Biomarkers for Mood May Alter Psychiatric Treatments 2Health News:National Survey Reveals Most Renters Want What They Do Not Have: On-Site Workout Facilities 2
... II Smart ValveTM, Hakim, H-V ... intelligent choice for meeting the ... Automatic pressure response causes the ... the conditions present, eliminating the ...
Codman Hakim Programmable valve cylindrical offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over t...
Leadpoint Micro-Electrode Recording...
... Using advanced 3D matching algorithms developed ... Stealthmerge automatically merges image sets from a ... and PET, regardless of acquisition orientation. Stealthmerge ... eliminating the requirement to scan tissue outside ...
Medicine Products: